Abcam PLC (NASDAQ:ABCZY) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Monday.

According to Zacks, “Abcam PLC distributes antibodies and associated protein research tools. Its product includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam PLC is headquartered in Cambridge, the United Kingdom. “

Shares of Abcam PLC (ABCZY) traded down $0.41 during midday trading on Monday, reaching $13.40. The company’s stock had a trading volume of 264 shares, compared to its average volume of 649. Abcam PLC has a 52-week low of $9.13 and a 52-week high of $15.22.

ILLEGAL ACTIVITY WARNING: This story was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/11/13/zacks-investment-research-lowers-abcam-plc-abczy-to-hold.html.

Get a free copy of the Zacks research report on Abcam PLC (ABCZY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Abcam PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam PLC and related companies with MarketBeat.com's FREE daily email newsletter.